Teva Pharmaceutical (TEVA) and Bar Pharma (BRL) Receives Merger Approval From European Commission
More News related to BRL
- Bearclaw Announces That Silver Quest Has Earned Interest in Capoose Property
- Bearclaw Announces That Silver Quest Has Earned Interest in Capoose Property
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Top 15 For 2008 (No. 14): M&A Wreckage
- Teva Pharmaceutical (TEVA) and Bar Pharma (BRL) Receives Merger Approval From European Commission
More News related to TEVA
- Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE(R)-Related Patents
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D(R) 12 Hour Tablets
- Teva Pharma (TEVA) Guides FY09, FY10 Inline With the Street
More News related to Mergers and Acquisitions
- Mexican Restaurants (CASA) Posts Q3 Loss of $0.07, Better Y/Y; Revs Down
- Cosi (COSI) Posts Q3 Loss of $0.06, Beats By 2c
- Enterprise GP Holdings (EPE) Posts Q3 EPS of $0.18, Misses Views
- Mindray Medical (MR) Tops Q3 EPS by 6c; Revs Light
- Neenah Paper (NP) Tops Q3 Views
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) have received approval from the European Commission to proceed with Teva's acquisition of Barr.
In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product overlap, representing approximately $6 million in the companies' annual sales. The companies continue to expect that the transaction will close this month.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. [SM]
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
